Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
1 - 99 . (canceled)
100 . A hapten-carrier conjugate comprising at least one hapten derived from nicotine and at least one carrier containing a T cell epitope and wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:
CJ 0
Q
CJ 1
(CH 2 ) n Q
CJ 1.1
CO 2 Q
CJ 1.2
COQ
CJ 1.3
OCH 3
CJ 2
OCO(CH 2 ) n Q
CJ 2.1
OCOCH═ Q
CJ 2.2
OCOCH(O)CH 2
CJ 2.3
OCO(CH 2 ) n CH(O)CH 2
CJ 3
CO(CH 2 ) n COQ
CJ 3.1
CO(CH 2 ) n CNQ
CJ 4
OCO(CH 2 ) n COQ
CJ 4.1
OCO(CH 2 ) n CNQ
CJ 5
CH 2 OCO(CH 2 ) n COQ
CJ 5.1
CH 2 OCO(CH 2 ) n CNQ
CJ 6
CONH(CH 2 ) n Q
CJ 7
Y(CH 2 ) n Q
CJ 7.1
CH 2 Y(CH 2 ) n Q
CJ 8
OCOCH(OH)CH 2 Q
CJ 8.1
OCO(CH 2 ) n CH(OH)CH 2 Q
CJ 9
OCOC 6 H 5
CJ 10
as identified in the application as FIG. 1b
CJ 11
YCO(CH 2 ) n COQ;
and wherein n is an integer, and Q is the carrier.
101 . A hapten-carrier conjugate according to claim 100 , wherein n is from about 2 to about 20.
102 . A hapten-carrier conjugate according to claim 100 , wherein Y is selected from the group consisting of S, O and NH.
103 . A hapten-carrier conjugate according to claim 100 , wherein the carrier is selected from:—proteins or peptides, bacterial toxins or products, subvirals, lectins, allergens and fragments of allergens, malarial protein antigen, artificial multi-antigenic peptides, and modifications, analogs and derivatives thereof.
104 . The hapten-carrier conjugate of claim 100 , wherein greater than one hapten is coupled to the carrier.
105 . A method of treating nicotine addiction in a mammal comprising administering a therapeutically effective amount of the hapten-carrier conjugate of claim 100 to a subject mammal.
106 . A method according to claim 105 , wherein said hapten-carrier conjugate is administered mucosally and comprises co-polymer microspheres optionally of poly(lactide-co-glycolide) co-polymer.
107 . A method according to claim 105 , wherein said hapten-carrier conjugate is administered as a topical preparation and which preparation optionally has a dynamic viscosity greater than water.
108 . A method according to claim 105 , wherein said hapten-carrier conjugate is administered as an injectible, sterile solution.
109 . A pharmaceutical preparation, which comprises (a) the hapten-carrier conjugate of claim 105 , and also (b) adjuvant.
110 . A process for preparing a conjugate according to claim 100 , which comprises linking the hapten and the carrier containing a T cell epitope by cross linking with a compound selected from: a carboxylic acid derived active ester, a mixed anhydride, an acyl azide, an acyl halide, an imino ester.